ANTEANA THERAPEUTICS, INC.

Biotech · Private

URB937, a peripheral FAAH inhibitor small molecule for pain management

Grants
$1.9M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · NAAA Inhibitors for pain and inflammation$223,903
Federal grantDepartment of Health and Human Services · Phase I · A new treatment for NSAID-associated gastrointestinal damage$150,000
Federal grantDepartment of Health and Human Services · Phase II · Peripheral FAAH as a target for novel analgesics$1,100,244
Federal grantDepartment of Health and Human Services · Phase II · Peripheral FAAH as a target for novel analgesics$398,227
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2417ProFound Therapeutics——
2418ECHOGENESIS THERAPEUTICS INC——
2419VASARYA THERAPEUTICS, INC.——
2420ANTEANA THERAPEUTICS, INC.——
2421ACHEMINALL CORPORATION——
2422CARDIOCREATE, INC.——
2423EVVIA THERAPEUTICS INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.